FDA Accepts Supplemental New Drug Application for Nebulized Tyvaso to Treat Idiopathic Pulmonary Fibrosis

United Therapeutics Corporation announced that the FDA has accepted its supplemental New Drug Application (sNDA) for nebulized Tyvaso (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF). If approved, nebulized Tyvaso would be the first and only inhaled anti-fibrotic treatment for this life-threatening lung disease. The FDA anticipates completing its review by late April 2027.